Am J Transplant, Volume 17, Suppl 3 Archives - Page 152 of 181 - ATC Abstracts

2017 American Transplant Congress
The Effect of Transplant Center Volume on Survival Outcomes for Patients Listed for Simultaneous Liver and Kidney Transplantation.
R. Modi,¹ D. Tumin,² E. Beal,^3,4 D. Hayes Jr.,^4,5 J. Hanje,^4,6 A. Michaels,^4,6 K. Washburn,^3,4 L. Conteh,^4,6 S. Black,^3,4 K. Mumtaz.^4,6
¹Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; ²Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, OH; ³General Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; ⁴Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH; ⁵Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH; ⁶Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH
This study examines the effect of center volume on survival differences between Simultaneous Liver Kidney Transplantation (SLKT) and liver transplantation alone (LTA).Methods: The United Network…
2017 American Transplant Congress
Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.
N. Lange,^1,2 D. Salerno,¹ C. Sammons.²
¹Department of Pharmacy, Weill Cornell Medical Center, New York, NY; ²Department of Pharmacy, Columbia University Irving Medical Center, New York, NY
BACKGROUND Basiliximab may be used to delay the initation of calcineurin inhibitors (CNI) in patients with renal injury after liver transplantation (LT). The optimal time…
2017 American Transplant Congress
Graft-versus-Host Disease Following Deceased Donor Liver Transplant.
K. Putchakayala, S. Skorupski, S. Farhan, M. Chaffins, S. Ilias, H. Pahari, K. Collins, S. Nagai, M. Abouljoud.
Henry Ford Hospital, Detroit, MI
We reviewed our institutional experience with graft-versus-host disease (GVHD) following orthotopic liver transplantation (OLT). All OLT from 10/1/2013-10/1/2016 were reviewed. Five cases of GVHD were…
2017 American Transplant Congress
Enhanced Recovery After Surgery Pathway for Living Donor Nephrectomy Patients Decreases Length of Stay and Narcotic Utilization.
R. Forbes,¹ A. King,² T. McGrane,² D. Hale,¹ W. Sandberg,² J. Wanderer,² M. McEvoy.²
¹Kidney and Pancreas Transplantation, Vanderbilt University Medical Center, Nashville, TN; ²Anesthesiology, Vanderbilt University Medical Center, Nashville, TN
Introduction:Enhanced recovery after surgery (ERAS) protocols reduce morbidity, hospital costs, and length of hospital stay although there have been few studies in living donor nephrectomy…
2017 American Transplant Congress
Interruption of RAAS in Hypertensive Proteinuric Kidney Donors.
O. Sanchez,¹ L. Ferrara,¹ D. Berglund,¹ A. Matas,² R. Foley,¹ H. Ibrahim.¹
¹Department of Internal Medicine, U of MN, Mpls, MN; ²Department of Surgery, U of MN, Minneapolis, MN
The aim of this analysis was to assess the progression of eGFR between proteinuric hypertensive living kidney donors (HTN-LKDs) receiving ACE inhibitors (ACEinh) or angiotensin…
2017 American Transplant Congress
Prognostic Histopathologic Characteristics in Recurrent IgA Nephropathy: The Clinical Significance of Vascular Change.
S. Park, H. Cho, M.-Y. Yu, Y. Kim, K. Moon, Y. Kim, H. Lee.
Seoul National University Hospital, Seoul, Korea
Background Although recurrent IgA nephropathy (IgAN) after kidney transplantation is known to cause lgraft failure, the clinical significance of histopathologic parameters in allografts needs further…
2017 American Transplant Congress
The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis.
D. Axelrod,¹ K. Lentine,² M. Schnitzler,² H. Xiao,² X. Lou,³ B. Orandi,³ J. Garonzik Wang,³ A. Massie,³ D. Segev.³
¹Surgery, East Carolina University, Greenville, NC; ²Transplant, Saint Louis University, St. Louis, MO; ³Surgery, Johns Hopkins University, Baltimore, MD
Incompatible living donor kidney transplant (ILDKT) has been established as an effective option for patients with willing but human leukocyte antigen incompatible live donors, reducing…
2017 American Transplant Congress
Multi-Stakeholder Perspectives on the Importance of Outcomes for Trials in Kidney Transplantation: An International Best Worse Scaling Survey.
M. Howell,^1,2 N. Evangelidis,^1,2 B. Sautenet,² G. Wong,^1,2,3 J. Craig,^1,2 K. Howard,¹ A. Tong.^1,2
¹School of Public Health, University of Sydney, Sydney, Australia; ²Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia; ³Centre for Transplant Research, Westmead Hospital, Sydney, NSW, Australia
To optimize the benefits of kidney transplantation, recipients and clinicians should have an agreed, shared management plan. This relies on prioritizing the same outcomes but…
2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
C. Durand, D. Brown, R. Wesson, N. Bhair, F. Naqvi, D. Ostrander, M. Bowring, A. Massie, S. Rasmussen, J. Sugarman, D. Segev, M. Sulkowski, N. Desai.
JHU, Baltimore, MD
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…
2017 American Transplant Congress
TACI Polymorphisms Associated with De Novo Alloantibodies in Humans and Allograft Rejection in Mice.
J. Platt,¹ E. Farkash,² A. Lefferts,¹ M. Samaniego,³ M. Cascalho.¹
¹Surgery, University of Michigan, Ann Arbor, MI; ²Pathology, University of Michigan, Ann Arbor, MI; ³Internal Medicine, University of Michigan, Ann Arbor, MI
A. Trans-membrane Activator and CAML Interactor (TACI) controls B cell differentiation and memory and exists as numerous allelic variants among healthy individuals and individuals with…